SG11201704897QA - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors - Google Patents

Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors

Info

Publication number
SG11201704897QA
SG11201704897QA SG11201704897QA SG11201704897QA SG11201704897QA SG 11201704897Q A SG11201704897Q A SG 11201704897QA SG 11201704897Q A SG11201704897Q A SG 11201704897QA SG 11201704897Q A SG11201704897Q A SG 11201704897QA SG 11201704897Q A SG11201704897Q A SG 11201704897QA
Authority
SG
Singapore
Prior art keywords
pyrazolopyrimidines
ubiquitin
pyrrolo
inhibitors
specific protease
Prior art date
Application number
SG11201704897QA
Inventor
Stephanos Ioannidis
Adam Charles Talbot
Bruce Follows
Alexandre Joseph Buckmelter
Minghua Wang
Ann-Marie Campbell
Darby Rye Schmidt
David Joseph Guerin
Justin A Caravella
R Bruce Diebold
Anna Ericsson
Jr David Lancia
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of SG11201704897QA publication Critical patent/SG11201704897QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201704897QA 2014-12-30 2015-12-29 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors SG11201704897QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462098141P 2014-12-30 2014-12-30
PCT/US2015/067831 WO2016109515A1 (en) 2014-12-30 2015-12-29 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors

Publications (1)

Publication Number Publication Date
SG11201704897QA true SG11201704897QA (en) 2017-07-28

Family

ID=55310894

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704897QA SG11201704897QA (en) 2014-12-30 2015-12-29 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors

Country Status (22)

Country Link
US (4) US9902728B2 (en)
EP (2) EP3623372A1 (en)
JP (1) JP6649388B2 (en)
KR (1) KR102581827B1 (en)
CN (1) CN107406451B (en)
AR (1) AR103297A1 (en)
AU (2) AU2015374170B2 (en)
CA (1) CA2972797C (en)
CL (1) CL2017001687A1 (en)
CO (1) CO2017006997A2 (en)
EA (1) EA038204B1 (en)
EC (1) ECSP17049010A (en)
ES (1) ES2768996T3 (en)
HK (1) HK1246284A1 (en)
IL (1) IL252773A0 (en)
MA (1) MA40706A1 (en)
MX (2) MX2017008604A (en)
PH (1) PH12017501224A1 (en)
SA (1) SA517381839B1 (en)
SG (1) SG11201704897QA (en)
TW (2) TWI770525B (en)
WO (1) WO2016109515A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102371532B1 (en) 2011-09-02 2022-03-07 인사이트 홀딩스 코포레이션 Heterocyclylamines as pi3k inhibitors
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
EP3200589A4 (en) 2014-09-10 2018-07-25 Temple University Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
TWI770525B (en) 2014-12-30 2022-07-11 美商瓦洛健康公司 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
MA41291A (en) 2014-12-30 2017-11-07 Forma Therapeutics Inc PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER
JP2018504430A (en) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
JP2018504432A (en) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド Isothiazolopyrimidinone, pyrazolopyrimidinone and pyrrolopyrimidinone as ubiquitin-specific protease 7 inhibitors
US9932351B2 (en) 2015-02-05 2018-04-03 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
NZ734993A (en) 2015-02-27 2024-03-22 Incyte Holdings Corp Salts of pi3k inhibitor and processes for their preparation
WO2017144633A1 (en) * 2016-02-25 2017-08-31 Asceneuron S. A. Glycosidase inhibitors
WO2017201683A1 (en) * 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
FR3061177B1 (en) * 2016-12-28 2019-09-27 Les Laboratoires Servier NOVEL HETERO (ARYL) -SUBSTITUTED PIPERIDINYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3052452B1 (en) * 2016-06-10 2018-06-22 Les Laboratoires Servier NOVEL PIPERIDINYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
RU2742271C2 (en) 2016-06-10 2021-02-04 Ле Лаборатуар Сервье Novel (hetero)aryl-substituted piperidinyl derivatives, a method for production thereof and pharmaceutical compositions containing them
WO2018009812A1 (en) 2016-07-08 2018-01-11 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
GB201612938D0 (en) * 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
SG11201903483VA (en) 2016-10-28 2019-05-30 Icahn School Med Mount Sinai Compositions and methods for treating ezh2-mediated cancer
TW201822637A (en) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 Substituted sulfonamides for controlling animal pests
AU2017370694A1 (en) 2016-12-08 2019-07-25 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating CDK4/6-mediated cancer
CN108239082B (en) * 2016-12-26 2021-01-05 成都先导药物开发股份有限公司 Compound for inhibiting ROCK and application thereof
EP3600290A4 (en) 2017-03-21 2020-08-12 Temple University - Of The Commonwealth System of Higher Education Novel modulators of the sigma-2 receptor and their method of use
EP3600289A4 (en) 2017-03-21 2020-08-05 Temple University - Of The Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents
MX2020002944A (en) 2017-09-14 2020-09-28 Daiichi Sankyo Co Ltd Compound having cyclic structure.
EP3700901A1 (en) 2017-10-24 2020-09-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-hydroxamate compounds and methods of use thereof
EA202091260A1 (en) * 2017-11-29 2020-09-07 Ле Лаборатуар Сервье NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIKVITIN-SPECIFIC PROTEASE 7
EA202091475A1 (en) 2017-12-15 2020-09-09 Пирамид Байосайенсиз, Инк. 5- (2- (2,5-DIFLUOROPHENYL) PYRROLIDIN-1-YL) -3- (1H-PYRAZOL-1-YL) PYRAZOLO [1,5-a] PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATMENT CANCER
CA3085460A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
GB201801562D0 (en) * 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
WO2019173516A1 (en) 2018-03-06 2019-09-12 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (akt) degradation / disruption compounds and methods of use
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
JP7301042B2 (en) 2018-03-30 2023-06-30 住友化学株式会社 Heterocyclic compound and harmful arthropod control composition containing the same
IL310857A (en) 2018-04-25 2024-04-01 Bayer Ag Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides
UY38291A (en) * 2018-07-05 2020-06-30 Servier Lab NEW AMINO-PYRIMIDONYL DERIVATIVES A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
CA3121376A1 (en) * 2018-12-06 2020-06-11 Almac Discovery Limited Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19)
CN109666005A (en) * 2018-12-14 2019-04-23 上海毕得医药科技有限公司 A kind of synthetic method of 2- bromine oxazole -5- Ethyl formate
CN114040760A (en) 2018-12-31 2022-02-11 拜欧米富士恩公司 Irreversible inhibitors of the MENIN-MLL interaction
WO2020142559A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
US20220125760A1 (en) 2019-02-14 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of usp7 inhibitors for the treatment of acute myeloid leukemia (aml)
CN109912598B (en) * 2019-03-27 2022-09-13 四川大学华西医院 Nucleoside derivative for preventing and treating inflammatory reaction and application thereof
WO2020207352A1 (en) * 2019-04-11 2020-10-15 四川科伦博泰生物医药股份有限公司 Triazine benzimidazole compounds and medical use thereof
CN112608320B (en) * 2020-01-16 2023-03-17 中国药科大学 Piperidine compound and preparation method and medical application thereof
GB202001980D0 (en) 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
WO2021211882A1 (en) * 2020-04-15 2021-10-21 Pyramid Biosciences, Inc. Methods for preparing tyrosine receptor kinase inhibitors
CN115715285A (en) * 2020-04-27 2023-02-24 奧土择破利悟 Compounds as UBR box domain ligands
AR123313A1 (en) * 2020-08-24 2022-11-16 Adama Makhteshim Ltd PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRAZOLES
WO2022159650A1 (en) * 2021-01-22 2022-07-28 Icahn School Of Medicine At Mount Sinai HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF eEF1A2
AU2022315201A1 (en) * 2021-07-20 2024-01-18 Dana-Farber Cancer Institute, Inc. Inhibitors targeting ubiquitin specific protease 7 (usp7)
CA3229150A1 (en) 2021-08-20 2023-02-23 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cance
GB202200753D0 (en) 2022-01-21 2022-03-09 Almac Discovery Ltd Pharmaceutical compounds
CN114957248B (en) * 2022-05-09 2023-12-29 南开大学 Pyrrolo pyrimidine compound and preparation method, pharmaceutical composition and application thereof

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5985863A (en) 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6008217A (en) 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
IN151496B (en) 1980-02-26 1983-05-07 Chamanlal Jagannath Shishoo
FI95572C (en) 1987-06-22 1996-02-26 Eisai Co Ltd Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt
JP2777159B2 (en) 1988-12-22 1998-07-16 エーザイ株式会社 Pharmaceuticals containing cyclic amine derivatives
US5124335A (en) 1991-01-30 1992-06-23 Merck & Co., Inc. Substituted pyrollo-fused 6 membered heterocycles as angiotensin ii antagonists
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US20120165319A1 (en) 1995-12-20 2012-06-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1 beta converting enzyme
FR2750862B1 (en) 1996-07-12 1998-10-16 Dupin Jean Pierre USE OF FUSED DIAZOTA HETEROCYCLES WITH AN AROMATIC OR HETEROAROMATIC SYSTEM FOR THE TREATMENT OF THROMBO-EMBOLIC DISEASES
DK0982992T3 (en) 1997-05-08 2002-10-14 Aventis Cropscience Uk Ltd Use of thienopyrimidines as fungicides
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
DE69828445D1 (en) 1998-04-23 2005-02-03 Reddys Lab Ltd Dr HETEROCYCLIC COMPOUNDS, AND THEIR USE IN MEDICAMENTS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF
US6720317B1 (en) 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US20060183776A9 (en) 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
ES2275670T3 (en) 2000-03-03 2007-06-16 EISAI R&D MANAGEMENT CO., LTD. NEW METHODS USING CHOLESTERASE INHIBITORS.
US20030153598A1 (en) 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
JP2003535864A (en) 2000-06-07 2003-12-02 アルミラル プロデスファルマ ソシエダ アノニマ 6-Phenylpyrrolopyrimidinedione derivative
AU2001268712A1 (en) 2000-06-23 2002-01-08 Bristol-Myers Squibb Company 1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor Xa inhibitors
JP2002105081A (en) 2000-07-28 2002-04-10 Nikken Chem Co Ltd Bicyclic compound of thiophene
PE20020394A1 (en) 2000-08-18 2002-06-21 Agouron Pharma PIRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, MODULATE AND / OR INHIBIT THE ACTIVITY OF ERAB / HADH2
US20020169175A1 (en) 2001-02-05 2002-11-14 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of heterocyclic compounds
US6960595B2 (en) 2001-03-23 2005-11-01 Bristol-Myers Squibb Pharma Company 5-6 to 5-7 Heterobicycles as factor Xa inhibitors
WO2003024456A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating and preventing migraines
WO2003032914A2 (en) 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
ATE521592T1 (en) 2002-03-13 2011-09-15 Janssen Pharmaceutica Nv HISTONE DEACETYLASE INHIBITORS
GB2405336A (en) 2002-05-01 2005-03-02 Eisai Co Ltd Cholinesterase inhibitors to prevent injuries caused by chemicals
US20070053976A1 (en) 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
AU2003298514A1 (en) 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
WO2004014908A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
EP1553947A4 (en) 2002-10-21 2006-11-29 Bristol Myers Squibb Co Quinazolinones and derivatives thereof as factor xa inhibitors
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
EP1460077B1 (en) 2003-03-18 2007-08-01 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Novel pyrazolopyrimidones and their use as PDE inhibitors
WO2004111014A1 (en) 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
EP1661896A4 (en) 2003-08-26 2008-07-16 Teijin Pharma Ltd Pyrrolopyrimidinethione derivative
US7557113B2 (en) 2003-08-26 2009-07-07 Teijin Pharma Limited Substituted pyrrolo[3,2-d]pyrimidine derivatives
WO2005035003A2 (en) 2003-09-22 2005-04-21 Dihedron Corporation Compositions and methods for increasing drug efficiency
US20050148534A1 (en) 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
KR101153335B1 (en) 2003-09-24 2012-07-05 메틸진 인코포레이티드 Inhibitors of histone deacetylase
US20080312189A1 (en) 2004-03-05 2008-12-18 Eisai Co., Ltd. Cadasil Treatment with Cholinesterase Inhibitors
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
NZ551004A (en) 2004-04-02 2010-07-30 Prana Biotechnology Ltd Neurologically-active compounds
JPWO2006004201A1 (en) 2004-07-01 2008-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 Nerve regeneration promoter
US20060172992A1 (en) 2004-08-13 2006-08-03 Eisai Co., Ltd. Therapeutic agent for overactive bladder resulting from cerebral infarction
US20060135507A1 (en) 2004-08-13 2006-06-22 Osamu Yokoyama Therapeutic agent for overactive bladder involved in aging
CN101048388A (en) 2004-08-31 2007-10-03 阿斯利康(瑞典)有限公司 Quinazolinone derivatives and their use as B-Raf inhibitors
JP5635726B2 (en) * 2004-09-14 2014-12-03 ミネルバ バイオテクノロジーズ コーポレーション Cancer diagnosis and treatment method
JP2006176503A (en) 2004-11-26 2006-07-06 Tohoku Univ Therapeutic agent for alzheimer's disease accompanied with cerebrovascular disorder
MX2007007483A (en) 2004-12-24 2007-07-20 Dainippon Sumitomo Pharma Co Bicyclic pyrrole derivatives.
JP5000490B2 (en) 2005-04-28 2012-08-15 武田薬品工業株式会社 Thienopyrimidone compounds
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
US7745447B2 (en) 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
AR056155A1 (en) 2005-10-26 2007-09-19 Bristol Myers Squibb Co ANTAGONISTS OF NON-BASIC MELANINE CONCENTRATION HORMONE RECEIVER 1
WO2007071738A1 (en) 2005-12-23 2007-06-28 Novartis Ag Condensed heterocyclic compounds useful as dpp-iv inhibitors
US20080119457A1 (en) 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
AR065081A1 (en) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc FUSIONATED QUINAZOLINONA AND PIRIMIDONA COMPOUNDS AND PHARMACEUTICAL COMPOSITION
CN101686952A (en) 2007-03-12 2010-03-31 Vm生物医药公司 Novel agents of calcium ion channel modulators
WO2008113255A1 (en) 2007-03-16 2008-09-25 The Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla Benzamide derivatives with anti-proliferative activity, pharmaceutical preparations thereof
WO2008116053A2 (en) * 2007-03-20 2008-09-25 Trustees Of Tufts College Fap-activated chemotherapeutic compounds, and methods of use thereof
WO2008138126A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
RU2341527C1 (en) 2007-07-17 2008-12-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Annelated asaheterocycles including pyrimidine fragment, method of production thereof and pi3k kinase inhibitors
RU2345996C1 (en) 2007-07-17 2009-02-10 Андрей Александрович Иващенко Annelated azaheterocyclic amides, which include pyrimidine fragment, method of obtaining and their application
US8648085B2 (en) * 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2009124259A1 (en) 2008-04-04 2009-10-08 Cv Therapeutics, Inc. Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
CA2737219C (en) 2008-08-11 2017-02-28 Tracy Keller Halofuginone analogs for inhibition of trna synthetases and uses thereof
US20110082158A1 (en) 2008-10-01 2011-04-07 Aleem Gangjee Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same
CN102316735A (en) 2008-12-23 2012-01-11 哈佛大学校长及研究员协会 The micromolecular inhibitor of gangrenosum acne apoptosis
BRPI1009398A2 (en) 2009-03-13 2016-03-08 Advinus Therapeutics Private Ltd substituted fused pyrimidine compounds
JP5722781B2 (en) 2009-08-26 2015-05-27 武田薬品工業株式会社 Fused heterocyclic derivatives and uses thereof
BR112012008518A2 (en) 2009-10-13 2016-04-05 Msd Oss Bv heterocyclic derivative and pharmaceutical composition
WO2011097607A1 (en) 2010-02-08 2011-08-11 Southern Research Institute Anti-viral treatment and assay to screen for anti-viral agent
US8575114B2 (en) 2010-03-23 2013-11-05 Albany Molecular Research, Inc. SGLT-2 inhibitors, methods of making them, and uses thereof
WO2012054332A1 (en) 2010-10-18 2012-04-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
JP2014515345A (en) * 2011-01-10 2014-06-30 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pyrimidinone derivatives as fatty acid synthase inhibitors
GB201107768D0 (en) 2011-05-10 2011-06-22 Univ Manchester Riboswitches
EP2565186A1 (en) * 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
US9394297B2 (en) 2012-02-28 2016-07-19 Amgen Inc. Amides as pim inhibitors
GB201205164D0 (en) 2012-03-23 2012-05-09 Almac Discovery Ltd Pharmaceutical compounds
JP2016504365A (en) 2012-12-28 2016-02-12 アメリカ合衆国 USP1 / UAF1 deubiquitinase complex inhibitor and use thereof
KR101446680B1 (en) 2013-02-08 2014-10-07 한국과학기술연구원 Thienopyrimidinone derivatives as mGluR1 antagonists
CN103833646A (en) 2014-02-28 2014-06-04 广东工业大学 Fatty amino substituted quinazolinone derivative and preparation method and application thereof
TWI770525B (en) 2014-12-30 2022-07-11 美商瓦洛健康公司 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
MA41291A (en) 2014-12-30 2017-11-07 Forma Therapeutics Inc PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER
JP2018504430A (en) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
JP2018504432A (en) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド Isothiazolopyrimidinone, pyrazolopyrimidinone and pyrrolopyrimidinone as ubiquitin-specific protease 7 inhibitors
US9932351B2 (en) 2015-02-05 2018-04-03 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors

Also Published As

Publication number Publication date
AU2021200346A1 (en) 2021-03-18
CN107406451A (en) 2017-11-28
ES2768996T3 (en) 2020-06-24
US10934299B2 (en) 2021-03-02
TWI698436B (en) 2020-07-11
CA2972797C (en) 2023-12-05
SA517381839B1 (en) 2022-05-30
JP6649388B2 (en) 2020-02-19
EP3240791A1 (en) 2017-11-08
ECSP17049010A (en) 2017-11-30
EP3240791B1 (en) 2019-11-06
EA038204B1 (en) 2021-07-22
MX2017008604A (en) 2017-11-15
MX2020002963A (en) 2020-07-22
AU2015374170B2 (en) 2020-10-22
JP2018500376A (en) 2018-01-11
BR112017013692A2 (en) 2018-01-09
TWI770525B (en) 2022-07-11
CN107406451B (en) 2019-12-17
US12018030B2 (en) 2024-06-25
MA40706A1 (en) 2018-02-28
IL252773A0 (en) 2017-08-31
CL2017001687A1 (en) 2018-03-23
WO2016109515A1 (en) 2016-07-07
US10377760B2 (en) 2019-08-13
EA201791507A1 (en) 2018-01-31
EP3623372A1 (en) 2020-03-18
KR102581827B1 (en) 2023-09-25
TW201639847A (en) 2016-11-16
US20180339988A1 (en) 2018-11-29
AR103297A1 (en) 2017-05-03
PH12017501224A1 (en) 2018-01-15
US9902728B2 (en) 2018-02-27
HK1246284A1 (en) 2018-09-07
US20190367525A1 (en) 2019-12-05
US20160185785A1 (en) 2016-06-30
CA2972797A1 (en) 2016-07-07
TW202115067A (en) 2021-04-16
AU2015374170A1 (en) 2017-07-27
KR20170106981A (en) 2017-09-22
US20210332052A1 (en) 2021-10-28
CO2017006997A2 (en) 2017-10-20

Similar Documents

Publication Publication Date Title
HK1246284A1 (en) Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
IL282103A (en) Purinones as ubiquitin-specific protease 1 inhibitors
HK1248221A1 (en) Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
HK1248222A1 (en) Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
HK1248220A1 (en) Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
IL252135B (en) Triazolopyrimidine compounds and uses thereof
IL248970A0 (en) Pyrazolopyridines and pyrazolopyrimidines
IL247949A0 (en) Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
IL253117A0 (en) Abrasive articles and methods for forming same
ZA201704300B (en) Nitrification inhibitor compositions and methods for preparing the same
IL252686A0 (en) Pyrazolopyridinamines as mknk1 and mknk2 inhibitors
EP3105010A4 (en) Abrasive article and method of using the same
GB201410226D0 (en) Methods and arrays for use in the same
IL252866B (en) Imidazopyridazine derivatives as pi3kbeta inhibitors
PL3240655T3 (en) Abrasive articles and methods for forming same
AU2014903744A0 (en) Nitrification inhibitors and formulations